Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. 2025 Annual Report Summary
Securities Code: 002370 Securities Abbreviation: Asia-Pacific Pharmaceutical Announcement No.: 2026-028
One, Important Notes
This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission.
All directors attended the board meeting to review this report.
Non-standard Audit Opinion Reminder □ Applicable Not Applicable
Board of Directors' Review of the Profit Distribution Plan or Capital Reserve to Share Capital Increase Plan for the Reporting Period □ Applicable Not Applicable
The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserve to share capital.
Board of Directors' Resolution on the Profit Distribution Plan for Preferred Shares in the Reporting Period □ Applicable Not Applicable
As of the end of the reporting period, the parent company has unappropriated losses. As of the end of the reporting period, the parent company's undistributed profits were -1,635,730,764.96 yuan, and the consolidated statement's undistributed profits were -1,690,956,707.64 yuan. The amount of unappropriated losses exceeds one-third of the total paid-in capital, and the company does not meet the conditions for cash dividends. Whether profit distribution can be implemented in the future will depend on the company's business improvement, profit accumulation, and the progress of offsetting unappropriated losses. Investors are kindly requested to pay attention to this situation and be aware of investment risks.